A main challenge of human papilloma (HPV)-based screening for cervical cancer is to adequately identify HPV-positive women at highest risk of cervical intraepithelial neoplasia grade 3 or worse, CIN31. The prognostic value of currently used adjunct markers (HPV16/18 genotyping and reflex cytology) may change after multiple rounds of HPV-based screening because of a change in the proportion of HPV-positive women with incident infections. To this end, we re-analyzed results from the POBASCAM trial (Population Based Screening Study Amsterdam). Women were randomized to HPV/cytology cotesting (intervention group) or to cytology-only (HPV blinded; control group) at enrolment. Our analytical population consisted of women with an HPV-positive result at the second round, 5 years after enrolment (n 5 381 intervention, n 5 392 control). Nine-year CIN31 risks were estimated by Kaplan-Meier. HPV-positive women were stratified by risk markers: HPV16/18 genotyping, reflex cytology and preceding HPV results. When comparing one to two rounds of HPV-based screening, the prognostic value of an abnormal cytology result did not change (40.0% vs. 42.3%, p 5 0.5617), but diminished for an HPV16/18 positive result (25.4% vs. 38.0%, p 5 0.0132). HPV16/18 genotyping was nondiscriminative in women with incident HPV infections (HPV16/18 positive 10.0% vs. negative 12.1%, p 5 0.3193). Women from the intervention group were more likely to have incident infections compared to women from the control group (incident screen-positive results 75.6% vs. 64.6%, p 5 0.001) Our results indicate that at a second round of HPV-based screening, risk differentiation by cytology remained strong, but was diminished for HPV 16/18 genotyping because of a larger proportion of incident infections.
adequately distinguish those HPV-positive women who are at highest risk and need immediate colposcopy referral from HPV-positive women who are at intermediate risk and need intensified follow-up.
14 Current HPV-based screening guidelines use reflex cytology and genotyping of HPV types 16 and 18 (HPV16/18) for further risk stratification of HPV-positive results. Both tests are FDA approved. [15] [16] [17] [18] [19] The performance of those adjunct risk markers has been evaluated in screening trial populations and observational cohorts. 5, [20] [21] [22] [23] [24] [25] While the results of these studies will be generalizable to the initial years following the transition to HPV-based screening programs-it has not yet been established whether the performance of these adjunct risk markers will be equally effective in later yearswhen all women have been invited at least once to an HPVbased screening visit. It may be hypothesized that subsequent HPV-based screening rounds mainly detect HPV infections with a relatively short duration of infection since lesions resulting from long-standing HPV infections presumably have been detected and treated in the preceding HPV screening round. Because the duration of infection is strongly driving the transformation towards CIN and eventually cervical cancer, these recent infections are expected to have a lower risk of CIN31 than infections detected in the first HPV-based screening round. [26] [27] [28] To assess if CIN31 risk stratification using HPV16/18 genotyping and reflex cytology is equally effective in subsequent HPV-based screening rounds as in the initial HPV-based screening round, we reanalyzed results from the randomized controlled clinical trial POBASCAM (Population Based Screening Study Amsterdam). 29 We compared the 9-year cumulative incidence of CIN31-stratified by HPV16/18 genotyping result, reflex cytology results and preceding HPV test resultsbetween HPV-positive women who were previously screened by cytology (control group) and HPV-positive women who were previously screened by HPV and cytology cotesting (intervention group).
Methods

Study design and procedures
The POBASCAM trial was conducted in the setting of the regular cervical cancer screening program in the Netherlands. The design has been published previously. 1, 2, 29, 30 In brief, the enrolment period lasted from 1999 to 2002 during which women attending routine cervical cancer screening visits (aged 29-61 years) were invited to participate. Eligible, consenting women were randomly assigned to the intervention (HPV and cytology cotesting) or control group (cytology with blinded HPV testing) (N 5 44,102). HPV DNA testing and conventional cytology were performed without knowledge of the other test result. The GP51/61 PCR-enzyme immunoassay (EIA) was used for HPV DNA testing and followed by reverse line blot analysis (RLB) on positive samples. 29, 31, 32 In the intervention group, women with cytology results of moderate dyskaryosis or worse (comparable to >ASC-US/ LSIL) were immediately referred for colposcopy, irrespective of their HPV result. Women with borderline or mild dyskaryosis (comparable to ASC-US/LSIL), were advised to repeat HPV testing and cytology at 6 and 18 months. HPV-positive women with normal cytology were also advised to repeat HPV testing and cytology at 6 and 18 months. Women with moderate dyskaryosis or worse and/or HPV-positive results at repeat testing were referred for colposcopy. HPV and cytology negative women (double negative) were invited to a next routine screening round after 5 years. In the control group, women with moderate dyskaryosis or worse were immediately referred for colposcopy. Women with borderline or mild dyskaryosis were advised to repeat cytology at 6 and 18 months. If repeat cytology also showed borderline dyskaryosis (or worse), women were referred for colposcopy. Women with normal cytology were invited to a next routine screening round after 5 years. At the second screening round after 5 years, participants in both study groups were managed according to the intervention group protocol. This means that women from the intervention group have been offered HPV-based screening twice whereas women from the control group have been offered HPV-based screening for the first time at the second screening round. At the third screening round after 10 years, participants in both study groups were managed according to the control group protocol, which was in line with the screening program at that time. Histological follow-up was obtained from participating laboratories and the nationwide histo-and cytopathology register (PALGA) until June 2013. The primary outcome measure of the current analysis was histologically confirmed CIN31 (including CIN-3, adenocarcinoma, squamous cell carcinoma and adenocarcinoma in situ). Analyses were also conducted for end-point CIN grade 2 or worse (CIN21). The analytical population included women aged 34-61 years at the second round, with an HPV positive test result at the second round who had no hysterectomy and no CIN21 detected during the first round (N 5 773).
All participants provided written informed consent. The trial was approved by the Medical Ethics Committee of the What's new? Testing for HPV infection has been widely adopted by cervical-cancer screening programs, along with cytology (Pap test). However, the authors of this study found that the prognostic value of HPV genotyping diminished after two rounds of HPV-based screening, while that for cytology remained the same. This was presumably due to a change in the proportion of HPV-positive women with short-term incident infections that may resolve quickly. Thus, revised guidelines for cervical-cancer triage may be needed in the future, to ensure more accurate screening.
VU University Medical Centre (number 96/103 A) and by the Ministry of Public Health (VWS nr 328.650) and is registered as ISRCTN20781131.
Statistical analyses
For the current analyses follow-up started counting at the start of the second screening round and only events occurring within 
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9 years after the start of the second screening round were included. Follow-up ended on the date of a CIN21 diagnosis or uterus extirpation. If the second screening round was the last attended screening round and no CIN21 or uterus extirpation was reported, follow-up was censored 4 years after the starting date of the second round. In all other women, follow-up ended 9 years after the start of the second round or on 30 June 2013, whichever came first.
We estimated the cumulative incidence of CIN31 and CIN21, stratified by HPV16/18 genotyping, reflex cytology and preceding HPV results in the intervention and control group using Kaplan-Meier method. Preceding HPV results were HPV results obtained at the start of the first screening round (enrolment) in the POBASCAM study. The preceding HPV result in the control group was blinded to the screening participant and physician. Cytology was reported abnormal when the result was borderline dyskaryosis or worse (ASC-US/LSIL) and normal otherwise. Greenwood formula was used to obtain 95% confidence intervals (95% CI). Differences in the 9-year (cumulative) risk of CIN31 and CIN21 between groups and within groups between risk-strata were compared using log-rank testing.
Finally, we examined the prognostic value of combinations of two and three adjunct risk markers among women from the intervention group. The selection of the adjunct risk markers in the combined risk marker analysis was based upon the log-rank statistic. These analyses were not conducted for the control group-because enrolment HPV results were not used for referral decisions.
Results
The trial profile is presented in Figure 1 . HPV DNA positivity at the second screening round in the trial was 4.0% in the intervention group and 4.2% in the control group and not statistically different (p 5 0.538). The median age at the second screening round among HPV-positive women was 40 years (IQR 36-49) in the intervention group; 40 years (IQR 37-49) in the control group. The proportion of women with HPV16/18 positive results was 34.7% in the intervention and 33.7% in the control group (p 5 0.776). The proportion of women with abnormal reflex cytology results was 25.5% in the intervention group and 29.7% in the control group (p 5 0.192). The proportion of women with incident screen-positive results was larger in the intervention group compared to the control Group (75.6% and 64.6% respectively, p 5 0.001). The median follow-up time was 6.7 years (IQR 4-7.8) and 6.5 years (IQR 4-7.8) in the intervention and control group respectively.
During 9-year follow-up after the start of the second screening round, 54 CIN31 (85 CIN21) lesions were detected among women in the intervention group and 72 (111 CIN21) among women in the control group. The respective 9-year CIN31 risks were 16.8% (95% CI 5 12.8 to 21.9) and 20.4% (95% CI 5 16.4 to 25.1, p 5 0.1062). The respective 9-year (Fig. 2) . HPV16/18 positive women had a significantly lower CIN31 and CIN21 risk in the intervention compared to the control group (CIN31 25.4% vs. 38.0%; p 5 0.0132; CIN21 33.4% vs. 45.5%; p 5 0.0253). In HPV16/18 negative women and in strata constructed based on reflex cytology or preceding HPV results, CIN31 and CIN21 risks were similar in women from the intervention and control group (Table 1) .
For all three risk markers -HPV16/18 genotyping, reflex cytology, and preceding HPV result-CIN31 and CIN21 risks were strongly increased in women with adjunct risk marker positive results (HPV16/18 positive, abnormal cytology and persistent screen-positive) compared to women with risk marker negative results (HPV16/18 negative, normal cytology and incident screen-positive respectively), both in the intervention and control group (all p < 0.01) ( Table 1) .
When classifying the three adjunct risk markers in the intervention group based on the log-rank statistic, reflex cytology was the strongest risk marker both for CIN31 (normal cytology 8.7% vs. abnormal cytology 40.0%, p < 0.0001) and for CIN21 (normal cytology 13.5% vs. abnormal cytology 55.3%, p < 0.0001). Further classification based on the log-rank statistic revealed preceding HPV results as the strongest CIN31 risk marker in both cytologically normal women (incident screen-positive 6.4% vs. persistent screenpositive 19.6%, p 5 0.0003) (Fig. 3a) and cytologically abnormal women (incident screen-positive 27.2% vs. persistent screen-positive 65.7%, p 5 0.0013) (Fig. 3b) . The respective CIN21 risks were also strongly related to preceding HPV result in both cytologically normal women (10.6% incident vs. 25.8% persistent, p 5 0.0004) and in cytologically abnormal women (47.2% incident vs. 73.5% persistent; p 5 0.0218) (not shown in Fig. 3) .
The use of screening results from a previous screening round may be logistically challenging. To study the performance of a program for settings in which the preceding HPV results are not available, we assessed the benefit of adding HPV16/18 genotyping to initial stratification by reflex cytology. This yielded only a significant effect in cytologically normal women (CIN31: HPV16/18 negative 6.0% vs. HPV16/18 positive 14.3%, p 5 0.0041; CIN21: 9.4% vs. 21.6%, p 5 0.0009) (Figs. 3c and 3d) but not in cytologically abnormal women (CIN31: 35.4% vs. 46.4%, p 5 0.3618; CIN21: 55.8.1% vs. 54.7%, p 5 0.9323). Cytology is a morphological test and its performance varies across countries. To study the performance of a program that uses only molecular HPV DNA tests, we assessed the benefit of adding HPV16/18 genotyping to initial stratification by preceding HPV results, the latter having the highest log-rank statistic value of the two. This yielded only a significant effect in women with persistent screen-positive results (CIN31: HPV16/18 negative 21.5% vs. HPV16/18 positive 53.2%, p 5 0.0131; CIN21: (Figs. 4a and 4b) .
Finally, by adding HPV16/18 genotyping to combined cytology-preceding HPV result strata, a significant HPV16/18 effect on CIN31 was observed in cytologically normal, persistent screen-positive women only (HPV16/18 negative 9.2% vs. HPV16/18 positive 36.3%; p 5 0.0414) ( Table 2 ). For end-point CIN21, a significant HPV16/18 effect was observed in both cytologically normal, incident screen positive women (HPV16/ 18 negative 8.3% vs. HPV16/18 positive 15.3%, p 5 0.0162), and cytologically normal, persistent screen-positive women (HPV16/18 negative 14.7% vs. HPV16/18 positive 43.0%, p 5 0.0426) ( Table 2 ).
Discussion
Our study indicates that risk stratification of HPV-positive women at subsequent HPV-based screening rounds may require a change in the screening guideline for HPV-positive women due to the increasing proportion of incident infections as compared to the initial HPV-based screening round. More specifically, we found a smaller number of persistent HPV infections and a slightly lower number of CIN31 and CIN21 cases after two rounds of HPV-based screening (intervention group) as compared to one round of HPVbased screening (control group). Furthermore, the CIN31 and CIN21 risk of HPV16/18-positive women was lower in the intervention than in the control group.
We hypothesized that once disease resulting from prevalent HPV infections has been removed from the screened population, screening intervals of 5 years (or shorter) are not long enough to use HPV16/18 genotyping for risk stratification of incident infections. Indeed, prognostic value of HPV16/18 genotyping for detection of CIN31 was negligible in women with preceding HPV-negative results, but was still substantial in women with preceding HPV-positive results. Reflex cytology, however, retained its discriminatory power in both women with incident and persistent screen-positive results. The proportion of screen-positive results which are attributable to incident infections will likely increase with each additional HPV-based screening round.
Other studies have already assessed the risk of CIN31/ CIN21 in HPV-positive women by strata of different adjunct risk markers at baseline, most often cytology and/or HPV16/ 18 genotyping. Khan et al. reported a 10-year cumulative incidence of CIN31 of 30% in HPV16-positive women with low grade squamous intraepithelial lesions (LSIL) on cytology compared to 4% in HPV16/18-negative women with LSIL cytology. 33 Castle et al. reported three to five times increased probability of immediate identification of CIN31 in women testing HPV-positive and adjunct risk marker positive (reflex cytology and/or HPV16/18 genotyping) compared to HPV- 
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positive and risk marker negative women. 21 Rijkaart et al. also reported a substantial higher 3-year cumulative risk of CIN31 in HPV-positive adjunct risk marker positive women (reflex cytology or HPV16/18 genotyping), compared to HPV-positive risk marker negative women. 20 Studies assessing CIN31/CIN21 risk over consecutive HPV-based screening rounds, reported lower risk after incident HPV screenpositive results compared to prevalent or first screening round HPV results. 4, 26, 27, [34] [35] [36] Several of them reported in addition that cytologically abnormal women with incident HPV screen-positive results have a higher risk on CIN21/ CIN31 compared to cytologically normal women with incident HPV screen-positive results. [34] [35] [36] Our study is in accordance with these studies but in addition provides evidence that HPV results at the previous round can be used as a risk stratifier during subsequent HPV-based screening rounds. Our study also adds results of risk stratification by HPV16/ 18 genotyping at the second HPV-based screening round and of different combinations of risk markers. Because of the randomized design, we were able to assess the effect of multiple rounds of HPV-based screening on the prognostic value of adjunct risk markers without having to adjust for age or cohort effects.
Our study has a few limitations. First, the representativeness of our results to a screening population may be hampered by the use of data from a population-based screening study with a specific screening and referral protocol. In the POBASCAM study, HPV-negative women with mild abnormal cytology were referred to intensified follow-up whereas in HPV-based screening programs HPV-negative women will be referred to the next screening visit without reflex cytology. Women with an enrolment HPV-negative result and concurrent abnormal cytology are thus underrepresented in our analytical population (selected at the second screening round). However, in the POBASCAM study <2% of women with an HPV-negative result at enrolment had concurrent abnormal cytology and only 2.4% of them had CIN31 detected during the first screening round, indicating that the influence of cotesting in the previous round is likely to be small. A similar limitation applies to HPV16/18 genotyping which was not included in the POBASCAM colposcopy referral protocol. However, if HPV16/18 positive women had directly been referred to colposcopy, irrespective of cytology, more HPV16/18 positive cases might have been detected during the enrolment screening round, further reducing the observed decrease in discriminatory power of HPV16/18 genotyping during the subsequent round. A second limitation of our study is that we have no information about colposcopy compliance and colposcopy evaluations without histological verification. This may have had some impact on the prognostic values of the adjunct risk markers since a biopsy has been taken more often among women referred on the basis of abnormal cytology than among women referred on the basis of an HPV positive result. In addition, we used data from the nationwide histo-and cytopathology registry PALGA, in which the diagnoses of the local pathologists were registered. We did not review the diagnosis of local pathologists but in earlier publications we showed that the inter-observer reliability of CIN31 was very high (absolute agreement 0.97).
2,29
With respect to risk stratification of HPV-positive women over multiple screening rounds, three different conclusions can be drawn from our results. First, our results indicate that HPV16/18 genotyping is especially meaningful during the first screening round. Only a small subgroup, i.e., women with persistent HPV screen-positive results and normal cytology, may still benefit from HPV16/18 genotyping in subsequent rounds. Second, cytology-detecting cellular changeswas shown to retain its discriminatory power also in women with incident HPV infections. Third, objective risk markers that can distinguish between transient infections and persistent (transforming) infections will become important to maintain a high discriminatory power among HPV infections detected during subsequent HPV screening rounds as the proportion of incident infections will increase. Examples of such risk markers which are currently in the pipeline include viral or host methylation markers, and p16/Ki-67 staining. 14 In conclusion, our results indicated that at a second round of HPV-based screening, cytology and preceding HPV results provided strong risk differentiation in HPV-positive women. HPV 16/18 genotyping was valuable in the first HPV-based screening round but its prognostic value diminished in the subsequent screening rounds because of an increase in the proportion of incident infections.
